NEW YORK ( TheStreet) -- Shares of Celldex Therapeutics (Nasdaq: CLDX) were gapping down Wednesday morning with an open price 13.4% lower than Tuesday's closing price. The stock closed at $3.88 Tuesday and opened today's trading at $3.36. The average volume for Celldex has been 312,100 shares per day over the past 30 days. Celldex has a market cap of $125.7 million and is part of the health care sector and drugs industry. Shares are down 5.8% year to date as of the close of trading on Tuesday. Celldex Therapeutics, Inc., a biopharmaceutical company, engages in the development, manufacture, and commercialization of targeted immunotherapies that prevent or treat specific forms of cancer, autoimmune disorders, and diseases caused by infectious organisms. The company has a P/E ratio of 38.6, above the S&P 500 P/E ratio of 17.7. TheStreet Ratings rates Celldex as a sell. The company's weaknesses can be seen in multiple areas, such as its unimpressive growth in net income, generally disappointing historical performance in the stock itself and feeble growth in its earnings per share. You can view the full Celldex Ratings Report. Get more investment ideas from our investment research center. Interested in other stocks that are gapping down? Get free SMS text alerts sent to you when the action happens by texting DOWN to 95370 or select from multiple alert options.